The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Nicholas A. Butowski on Convection-Enhanced Delivery of Nanoliposomal Irinotecan in Brain Cancer

Nicholas A. Butowski, MD
Published Online:9:08 PM, Mon February 8, 2016

Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging. 

Butowski encourages any medical professional who is treating a patient with either a grade 3 or 4 recurrent brain tumor to refer that patient to an institution to receive nanoliposomal irinotecan. He adds while the treatment may take 2 or 3 hours, depending on the patient, the treatment is targeted with an MRI so medical professionals can be as accurate as possible.

Butowski likens the delivery of nanoliposomal irinotecan to the Poliovirus trial at Duke University, though without the blind delivery. Butowski adds that while the convection-enhanced delivery method was prohibitively expensive in the past, the treatment may slowly become more widespread.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.